Look at the announcement, Xiao E is the first to report!

Zhizhen Technology: The application for issuing shares to specific targets was accepted by the Shenzhen Stock Exchange

Zhizhen Technology (003007) announced on the evening of November 17 that the Shenzhen Stock Exchange checked the application documents submitted by the company for the issuance of shares to specific objects, and decided to accept the application documents when it considered that the application documents were complete.

Nanshan Zhishang: The application for the issuance of shares to specific targets was approved by the Listing Review Center of the Shenzhen Stock Exchange

Nanshan Zhishang (300918) announced on the evening of November 17 that the Shenzhen Stock Exchange's issuance and listing review agency reviewed the company's application documents for issuing shares to specific objects, and believed that the company met the issuance conditions, listing conditions and information disclosure requirements, and the Shenzhen Stock Exchange will report to the China Securities Regulatory Commission to perform the relevant registration procedures in accordance with the regulations.

*ST Xinning: The application for the issuance of shares to specific targets was approved by the Listing Review Center of the Shenzhen Stock Exchange

*ST Xinning (300013) announced on the evening of November 17 that the Shenzhen Stock Exchange's issuance and listing review agency reviewed the company's application documents for issuing shares to specific objects, and believed that the company met the issuance conditions, listing conditions and information disclosure requirements, and the Shenzhen Stock Exchange will report to the China Securities Regulatory Commission to perform the relevant registration procedures in accordance with the regulations.

Blonde Rabi: The company acquired 51% of the shares of Zhuhai Hanfei and Zhongshan Hanfei in cash and controlled them

Blonde Rabi (002762) announced on the evening of November 17 that the company intends to acquire 51% of the equity of Zhuhai Hanfei Medical Beauty Clinic Co., Ltd. (hereinafter referred to as "Zhuhai Hanfei") wholly owned by Guangdong Hanfei Hospital Investment Co., Ltd. (hereinafter referred to as "Hanfei Investment") for 41.2767 million yuan, and 51% of the equity of Zhongshan Hanfei Medical Beauty Clinic Co., Ltd. (hereinafter referred to as "Zhongshan Hanfei") wholly owned by Hanfei Investment for 10.1269 million yuan. Hanfei Investment is a shareholding company of the Company, and this transaction constitutes a connected transaction. After the completion of this transaction, Zhuhai Hanfei and Zhongshan Hanfei will be included in the company's consolidated financial statements.

Tianjin Investment Urban Development: The proposed transfer of the equity of the subsidiary is expected to constitute a major asset restructuring

Tianjin Investment Urban Development (600322) announced on the evening of November 17 that the company intends to transfer 90% of the equity of the holding subsidiary Huachi Company, 46.33% of the equity of the shareholding subsidiary Huafugong Company and 31.89% of the equity of the shareholding subsidiary Tianfang Property Company through public listing or non-public agreement transfer. According to preliminary estimates, this transaction is expected to constitute a major asset restructuring. The counterparty of this transaction is not clear, the transaction contract has not been signed, there is no performance arrangement, and the main content of the contract such as the final transaction price and payment method cannot be determined at present.

Zhongsheng Pharmaceutical: The phase II clinical trial of onladivir granules completed the enrollment and dosing of the first participant

Zhongsheng Pharmaceutical (002317) announced on the evening of November 17 that the phase II clinical trial of the first participant enrollment and dosing of the first participant in the treatment of patients aged 2-17 years old with the first phase of the innovative drug Onladivir Granules (R&D code: ZSP1273 Granules) independently developed by Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd., a holding subsidiary of the company. The results of preclinical studies showed that the inhibitory ability of onladivir against a variety of influenza A viruses was significantly better than that of the neuraminidase inhibitor oseltamivir and the endonuclease inhibitor mabaloxavir, and it had a strong inhibitory effect on oseltamivir-resistant virus strains, mabaloxavir-resistant virus strains and highly pathogenic avian influenza virus strains.

Wanbangde: Chlorpromazine hydrochloride tablets obtained the registration approval for consistency evaluation

Wanbond (002082) announced on the evening of November 17 that Wanbond Pharmaceutical Group Co., Ltd., a wholly-owned subsidiary of the company, recently received the "Notice of Approval of Drug Supplementary Application" for chlorpromazine hydrochloride tablets approved and issued by the State Drug Administration. Chlorpromazine hydrochloride tablets are phenothiazine antipsychotics, which can be used to treat schizophrenia, mania, etc., and can also be used for vomiting, vomiting or intractable hiccups caused by various reasons. The company's chlorpromazine hydrochloride tablets are the first in China to pass the consistency evaluation.

Junshi Biosciences: toripalimab was approved by the UK Medicines and Healthcare products Regulatory Agency for marketing authorization

Junshi Biosciences (688180) announced on the evening of November 17 that the company's wholly-owned subsidiary, TopAlliance Biosciences Inc., has obtained marketing authorization from the UK Medicines and Health Products Agency (MHRA) for the treatment of two indications: toripalimab in combination with cisplatin and gemcitabine for relapse, inoperable or radiotherapy, or first-line treatment of adult patients with metastatic nasopharyngeal carcinoma, and toripalimab in combination with cisplatin and paclitaxel for first-line treatment of adult patients with unresectable advanced/recurrent or metastatic esophageal squamous cell carcinoma. Toripalimab became the first and only drug for the treatment of nasopharyngeal carcinoma in the UK, and the only first-line treatment for advanced or metastatic esophageal squamous cell carcinoma with no restriction on PD-L1 expression.

Hailiang shares: The company's copper pipe exports are very little affected by the adjustment of tax rebates

Hailiang Co., Ltd. (002203) announced on the evening of November 17 that on November 15, 2024, according to the Announcement No. 15 of 2024 issued by the Ministry of Finance and the State Administration of Taxation "Announcement on Adjusting the Export Tax Rebate Policy", it will be implemented from December 1, 2024, and the export tax rebate rate of some refined oil, photovoltaics, batteries, and some non-metallic mineral products will be reduced from 13% to 9%; Abolish export tax rebates for aluminum, copper, chemically modified animal, vegetable or microbial oils, greases and other products. The adjustment of the export tax rebate policy, the cancellation of the export tax rebate of aluminum, copper and other products, mainly involves the company's copper tube product exports, and more than 90% of the company's product exports are carried out in the form of import processing, and the import processing business model is based on processing fees, which is very little affected by the tax rebate adjustment. After the introduction of the new policy, the company actively adjusted its business strategy, and from November 18, 2024, all product exports will be adjusted to processing with supplied materials or imported processing.

Junyi Digital: Shareholder Guo Jin plans to reduce his holdings of no more than 2.44% of the company's shares

Junyi Digital (301172) announced on the evening of November 17 that Guo Jin, a shareholder holding 6.7% of the shares, plans to reduce his holdings of the company's shares by centralized bidding and block trading within 3 months after 15 trading days, with a total of no more than 3 million shares, accounting for no more than 2.44% of the company's total share capital.

Nanning Department Store: Shareholder Nanning Futian intends to reduce its holdings of no more than 0.73% of the company's shares

Nanning Department Store (600712) announced on the evening of November 17 that Nanning Futian Investment Co., Ltd., a shareholder of 0.73% of the company, intends to reduce the total number of shares of Nanning Department Store by bidding transactions and block transactions by no more than 3.9993 million shares, that is, no more than 0.73% of the total share capital of Nanning Department Store.

Wanfeng shares: Ningbo Yixian plans to reduce its holdings of no more than 3% of the company's shares

Wanfeng shares (603172) announced on the evening of November 17 that Ningbo Yixian Enterprise Management Consulting Co., Ltd. (hereinafter referred to as "Ningbo Yixian"), a specific shareholder holding 3.75% of the company's shares, plans to reduce its holdings of the company's shares by block trading no more than 2,667,600 shares, that is, no more than 2% of the company's current total share capital; It is planned to reduce the company's shares by centralized bidding by no more than 1,333,800 shares, that is, no more than 1% of the company's current total share capital; It will be carried out within 90 days after 15 trading days from the date of the announcement of this shareholding reduction plan.

Weiguang Biotech: Signed a strategic cooperation agreement with Shenzhen University of Technology

Weiguang Biotechnology (002880) announced on the evening of November 17 that the company and Shenzhen University of Technology jointly promoted the integration of industry and education in the field of life and health, strengthened the cooperation of industry, university and research, and signed the "Strategic Cooperation Agreement" on November 14 with the goal of building a national science and technology park, promoting the upgrading of the life and health industry, and promoting regional economic development. This agreement does not involve specific transaction amounts and transaction matters, and is not a related party transaction.

Bozhon Seiko: Suzhou Zhonger intends to transfer 5.426% of the company's shares by agreement

Bozhon Seiko (688097) announced on the evening of November 17 that Suzhou Zhonger, the concerted action person of the company's controlling shareholder Bozhon Group, signed the "Equity Transfer Agreement" with Xinke Hongchuang, intending to transfer 24,235,100 unrestricted tradable shares (accounting for 5.426% of the company's total share capital) to Xinke Hongchuang through agreement transfer, with a transfer price of about 477 million yuan. After the completion of the transfer agreement, Suzhou Zhonger still directly holds 130 million shares of the listed company, accounting for 29.216% of the company's total shares. Xinke Hongchuang directly holds 24,235,100 shares of the company, accounting for 5.426% of the company's total shares. This change in equity does not involve the reduction of the actual controller and its persons acting in concert, does not affect the tender offer, and will not lead to a change in the controlling shareholder and actual controller of the company.

Gujia Home: The shares held by shareholder Gujia Group have been frozen

Gujia Home Furnishing (603816) announced on the evening of November 17 that the company's shares held by Gujia Group, a shareholder of 12.55%, were frozen by the queue for a total of 103 million shares, accounting for 100% of the company's shares held by it. Gujia Group is not the controlling shareholder and actual controller of the company, and this matter will not lead to a change in the control of the company and will not affect the daily operation and management of the company.

Peneng Technology: Wei Zaisheng, chairman of the company, lifted the retention measure

Peneng Technology (688063) announced on the evening of November 17 that the controlling shareholder ZTE received the "Notice of Lifting Lien" issued by the Yongqing County Supervision Commission, and the Yongqing County Supervision Commission has lifted the retention measures against the company's chairman Wei Zaisheng. At present, Wei Zaisheng can normally perform the duties of the chairman and legal representative of the company, and Zhai Weidong, the director of the company, no longer performs the relevant duties of the chairman and legal representative.

*ST Jingfeng: Abnormal fluctuations in stock trading are suspended for verification

* ST Jingfeng (000908) announced on the evening of November 17 that the company's shares rose by 752.78% from July 3 to November 15, and the stock price fluctuated greatly, and investors paid more attention to it. After the company's application, the company's shares will be suspended from the opening of the market on November 18, 2024, and will resume trading after the verification is completed and relevant announcements are disclosed, and the suspension is expected to last no more than 3 trading days.